New ALS drug targets genetic cause in early human trial
Disease control
Recruiting now
This study tests an investigational drug called LTX-002 in people with amyotrophic lateral sclerosis (ALS). The drug is designed to target a specific genetic message linked to the disease. The main goal is to check the drug's safety and tolerability, and to see how it moves throu…
Phase: PHASE1, PHASE2 • Sponsor: Leal Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC